Background: Previous studies suggested that adiponectin (APN) could ameliorate ischemia/reperfusion injury and endothelial dysfunction in patients with acute myocardial infarction. However, the relationship between serum APN level and coronary flow after primary percutaneous coronary intervention (PPCI) in patients with STsegment elevation myocardial infarction (STEMI) is unclear.
| INTRODUC TI ON
Adiponectin (APN), a type of adipocytokine, is secreted from the adipose tissue. Previous studies have demonstrated a significant association of hypoadiponectinemia with the occurrence of acute myocardial infarction (AMI). 1, 2 But the relationship between plasma APN level and prognosis of AMI remains controversial. [3] [4] [5] [6] [7] [8] [9] Several clinical trials have suggested an inverse correlation of circulating APN level with adverse outcomes in patients with AMI. [7] [8] [9] However, the results of other studies are contradictory. [3] [4] [5] [6] Animal studies showed that myocardial ischemia/reperfusion (MI/R) injury was severe in the APN knockout mice, which was ameliorated by administering exogenous APN. 10, 11 Also, APN could improve vascular endothelial function via its ability to increase nitric oxide production. 12, 13 However, it is still unclear whether APN could protect the cardiomyocytes and improve coronary flow in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI).
The no-reflow/slow-flow phenomenon is common in patients with STEMI after reperfusion therapies, and it is associated with major adverse cardiac events (MACE). 14, 15 The pathophysiology of no reflow or slow flow involves microembolization, microvascular spasm, microcirculation disturbance, and MI/R injury. 16 The cardioprotective effect of APN might be related to good myocardial perfusion and clinical outcomes in patients treated with PPCI.
The present study investigated the association between APN on admission and the related indicators of myocardial damage and coronary blood flow in STEMI patients undergoing PPCI. We also aimed to observe the relationship between APN and prognosis in these patients. 
| MATERIAL S AND ME THODS

| Participants
| Coronary angiography and PPCI
All participants received the standard therapies of STEMI before and after PPCI. Once a diagnosis of STEMI was confirmed, PPCI was performed immediately by experienced interventional cardiologists after the administration of 300 mg aspirin and 600 mg clopidogrel as loading doses. At least one drug-eluting stent was implanted in the culprit lesion of infarct-related artery (IRA). Dual antiplatelet therapy (100 mg aspirin and 75 mg clopidogrel per day) was continued for 12 months, and then, single antiplatelet therapy (100 mg aspirin per day) was maintained.
Coronary angiograms were interpreted by two independent cardiologists in the catheterization laboratory. Thrombolysis In Myocardial Infarction (TIMI) flow grade (TFG) 3 was defined as complete coronary flow within three cardiac cycles, whereas TFG <3 denoted incomplete perfusion or complete perfusion over three cardiac cycles. The corrected TIMI frame count (CTFC) was calculated using the method previously described in which the frames were counted according to the contrast that flowed from the ostium of the target vessel to the distal landmark branch. 17 In addition, the CTFC of the left anterior descending artery was adjusted by dividing by 1.7.
| Blood sampling
Venous blood samples were obtained from peripheral veins before the PPCI procedure. The serum APN level was determined using the enzyme-linked immunosorbent assay, and other biomarkers, such as interleukin-6 (IL-6), leptin, and high-sensitive C-reactive protein (Hs-CRP), were measured simultaneously. The results of laboratory examinations, including routine blood parameters, renal function, uric acid, lipid, glucose, albumin, creatine kinase (CK)-MB, and N-terminal pro-brain natriuretic peptide (NT-proBNP), were also compared in this study.
| Clinical follow-up
Major adverse cardiac events, defined as death, nonfatal reinfarction, and requirement of hospitalization for unstable angina pectoris (UAP) or decompensated heart failure (HF), were observed during the follow-up period that lasted until March 2018. All patients were followed up for at least 3 years or until an endpoint occurred. The follow-up data were collected from the medical records, patients, and/or their families by telephone interviews and/or outpatient visits. Results were expressed as odds ratio (OR) and confidence interval (CI). Univariate and multivariate Cox proportional hazards regression analyses were used to find out the factors associated with MACE by calculating hazard ratios (HRs) and 95% CI. All variables with P < 0.15 on the univariate analysis were entered into the multivariate model using the step-wise backward selection method, and a P value <0.05 was set for inclusion in the multivariate model. 
| Statistical analysis
| RE SULTS
| Comparison of baseline characteristics
In this study, data of APN on admission displayed a normal distribution, and the mean serum APN level was 13.56 ± 2.14 μg/mL. The patients were divided into two groups based on the average APN level on admission: low-APN group (n = 77, APN <13.56 μg/mL) and high-APN group (n = 67, APN ≥13.56 μg/mL).
The baseline clinical characteristics and concomitant medications of the two groups are shown in Table 1 . No significant differences were found in baseline characteristics, including age, sex, coronary risk factors, obesity indexes, blood pressure, and heart rate on admission, between groups. The prevalences of HF and anterior myocardial infarction, as well as the time of symptom to admission and door to balloon, were similar in the two groups. All patients received dual antiplatelet therapy and other conventional medications according to the individual condition. No differences in concomitant medications were observed between the two groups.
| Comparison of laboratory parameters and circulating biomarkers
The laboratory parameters and circulating biomarkers were measured and compared; the results are shown in Table 2 . The levels of peak CK-MB and IL-6 on admission were significantly lower in the high-APN group compared with the low-APN group (P = 0.032 and P = 0.003, respectively). In addition, no significant differences were observed in other laboratory indicators between groups, including Hs-CRP, leptin, and peak NT-proBNP. Table 3 summarizes the angiographic characteristics of the two groups. All patients enrolled in this study underwent PPCI, and the mean number of stents implanted in IRA was 1.15 ± 0.49. No significant differences were noted in the location of IRA and the severity of coronary artery disease between groups. Neither the proportions of using single stent and thrombus aspiration nor the prevalence of initial TFG 0 was obviously different in the two groups. In the high-APN group, the prevalence of TFG 3 after the procedure was higher (P = 0.032), whereas the CTFC after PPCI was lower (P = 0.029), compared with the low-APN group.
| Comparison of coronary imaging characteristics
| Predictor of poor coronary flow after PPCI
As shown in Table 4 , variables that might affect the coronary flow were brought into the logistic regression analyses. Through the univariate regression analysis, Gensini score, door-to-balloon time ≥90 minutes, and APN on admission were entered into the multi- demonstrated that APN was an independent negative predictor of poor coronary flow after reperfusion therapy (OR = 0.72, 95% CI:
0.56-0.93, P = 0.011).
| MACE
The median follow-up time was 41 months (interquartile range [39] [40] [41] [42] [43] [44] [45] . Altogether, eight patients, four in each group, died in the 3-
year follow-up period. Of these, two patients died during hospitalization. No significant differences were observed in the rates of death and nonfatal reinfarction between groups. However, the incidences of rehospitalization for UAP or HF and total MACE were significantly lower in the high-APN group than those in the low-APN group during the 3-year follow-up (P = 0.017 and P = 0.019, respectively; Table 5 ).
Kaplan-Meier curves indicated that the patients in the high-APN group had a better MACE-free survival rate (P = 0.043; Figure 1 ). 
| Predictors of MACE
| D ISCUSS I ON
ST-segment elevation myocardial infarction is a severe cardiovascular disease causing high mortality. [18] [19] [20] In addition, patients with STEMI tend to suffer from HF. 21 However, currently available Better coronary flow and less myocardial necrosis are associated with better clinical outcomes for patients with STEMI. This study showed that the elevated APN level on admission was related to improved myocardial reperfusion evaluated by TFG and CTFC. And we found that APN was an independent negative predictor of poor coronary flow after PPCI. Experimental data confirmed the cardiovascular protective effects of APN, [23] [24] [25] which could stabilize artery plaques and protect against myocardial damage. [26] [27] [28] Several studies demonstrated that APN could also reduce MI/R injury and improve coronary blood flow in both animal models and humans. 10, 11, [24] [25] [26] Trifunovic et al 29 reported that the plasma APN level on admission significantly positively correlated with coronary flow reserve, In this study, the concentrations of peak CK-MB and IL-6 significantly decreased in the high-APN group. It was reported that the levels of peak CK-MB and IL-6 positively correlated with the myocardial infarct size. 30, 31 In addition, increased CK-MB and IL-6 levels repre- The relationship between APN and the severity of coronary artery disease is still unclear, especially in patients with AMI. A few studies showed that the reduced APN level was associated with severe coronary stenosis and high atherosclerotic burden. 40, 41 However, their findings were not confirmed in other studies. 42, 43 Similarly, no obvious correlation between the APN level and the se- The present study had several limitations. Firstly, it was a single-center and small-sample study, which did not exclude all the interference factors. Therefore, larger and more rigorous clinical trials are required to support the findings. Secondly, despite a decrease in total MACE in the high-APN group, no significant differences were found in hard endpoints including all-cause death and nonfatal reinfarction. The relationship between APN and clinical outcomes in patients with STEMI is still uncertain due to the inconsistency in previous findings. Thirdly, this study found a relationship between serum APN level and myocardial blood flow after PPCI, but the mechanism was not fully explained. The pathophysiology of coronary flow regulated by APN needs further investigation.
In conclusion, a higher serum APN level on admission correlated with better myocardial blood flow and less myocardial damage in patients with STEMI undergoing PPCI. Also, the increased serum APN level could predict good clinical outcomes in such populations. 
